Kenvue Inc. (KVUE)

NYSE: KVUE · Real-Time Price · USD
18.43
-0.19 (-1.02%)
At close: Sep 8, 2025, 4:00 PM
18.55
+0.12 (0.65%)
After-hours: Sep 8, 2025, 7:12 PM EDT
-1.02%
Market Cap35.37B
Revenue (ttm)15.14B
Net Income (ttm)1.42B
Shares Out 1.92B
EPS (ttm)0.74
PE Ratio24.90
Forward PE17.20
Dividend$0.82 (4.45%)
Ex-Dividend DateAug 13, 2025
Volume56,122,487
Open18.75
Previous Close18.62
Day's Range18.20 - 18.93
52-Week Range17.15 - 25.17
Beta0.78
AnalystsBuy
Price Target24.21 (+31.36%)
Earnings DateNov 6, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]

IPO Date May 4, 2023
Employees 22,000
Stock Exchange NYSE
Ticker Symbol KVUE
Full Company Profile

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Financial Statements

Analyst Summary

According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $24.21, which is an increase of 31.36% from the latest price.

Price Target
$24.21
(31.36% upside)
Analyst Consensus: Buy
Stock Forecasts

News

S&P 500 Losers: From Lululemon To MGM — What Went Wrong?

During the week ending September 5, the S&P 500 was essentially unchanged, slipping 0.12%. In contrast, several notable S&P 500 stocks fell sharply, driven by a mix of earnings outlook revisions, regu...

Other symbols: LULUMGMSTZTDG
8 hours ago - Forbes

Tylenol maker's stock dips after report says RFK Jr.'s HHS plans to link the drug to autism

The U.S. Department of Health and Human Services (HHS) is planning to release a report that will reportedly link autism and acetaminophen use in pregnancy, according to The Wall Street Journal. The de...

10 hours ago - Fast Company

Explainer: Is Tylenol safe to take during pregnancy?

U.S. Health Secretary Robert F. Kennedy Jr. plans to announce a link between autism and prenatal exposure to the popular over-the-counter pain and fever medicine Tylenol, sold generically as acetamino...

3 days ago - Reuters

Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol

Dr. Scott Gottlieb, fmr. FDA commissioner, joins 'Fast Money' with reaction to RFK Jr. implying Tylenol usage is linked to autism, sending Kenvue stock plummeting.

3 days ago - CNBC Television

Kenvue fights back against Tylenol safety concerns as its stock tumbles

Kenvue rushed to the defense of Tylenol, but the stock still suffered a record selloff on news that RFK Jr. will release a report linking the use of acetaminophen during pregnancy to autism.

3 days ago - Market Watch

Tylenol Maker Kenvue's Stock Slumps Following Report RFK Jr. Will Link It to Autism

Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.

3 days ago - Investopedia

Tylenol-maker shares sink after report says RFK's HHS will link to autism

Shares in the the parent company of Tylenol-maker McNeil Consumer Healthcare sank after a report suggested Robert F. Kennedy Jr.'s HHS will name the drug as a potential cause of autism.

3 days ago - Fox Business

RFK Jr. Report Will Link Autism To Tylenol Use During Pregnancy, Report Says

A promised report from Health and Human Services Secretary Robert F. Kennedy Jr. will claim the use of the common painkiller Tylenol during pregnancy is a potential cause for autism, The Wall Street J...

3 days ago - Forbes

RFK Jr. To Link Tylenol Use To Autism: Report

Health Secretary Robert F. Kennedy Jr. is preparing to release a report suggesting that the use of a common over-the-counter pain reliever during pregnancy may be tied to a higher risk of autism.

3 days ago - Benzinga

Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Shares of Kenvue fell more than 10% on Friday after a report that Health and Human Services Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company's pain medication Tylenol ...

3 days ago - CNBC

Kennedy and HHS to link use of Tylenol use in pregnancy to autism, WSJ reports

U.S. Health Secretary Robert F. Kennedy Jr. plans to announce that use of over-the-counter pain medication Tylenol in pregnant women is potentially linked to autism in a report that will also suggest ...

3 days ago - Reuters

Best Dividend Aristocrats For September 2025

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...

12 days ago - Seeking Alpha

Kenvue Can't Be Written Off Yet

Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board,...

21 days ago - Seeking Alpha

Kenvue attracts share purchase by activist investor Sachem Head

Band-Aid and Tylenol maker Kenvue attracted the attention of another activist investor in the second quarter, with Sachem Head Capital Management reporting that it bought into the stock.

24 days ago - Reuters

Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript

Kenvue, Inc. (NYSE:KVUE) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amit Banati - Chief Financial Officer Kirk L. Perry - Interim CEO & Director Sofya Tsinis - He...

4 weeks ago - Seeking Alpha

Kenvue meets profit estimates amid strategic review

Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic review at the consumer health company.

4 weeks ago - Reuters

Kenvue Reports Second Quarter 2025 Results

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining b...

4 weeks ago - Business Wire

Should You Buy Kenvue Stock At $22?

Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encomp...

4 weeks ago - Forbes

Kenvue Increases Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent in...

5 weeks ago - Business Wire

20 Kiplinger July Dividend Favorites: No Cigars

Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d...

Other symbols: APDBDXDUKEPDGSHDJNJ
6 weeks ago - Seeking Alpha

Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and w...

6 weeks ago - Business Wire

Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down. Kenvue shares were up by more than 6...

2 months ago - Invezz

Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.

The company, formerly part of Johnson & Johnson, says it is taking steps ‘to accelerate profitable growth.'

2 months ago - Barrons

Kenvue CEO steps down

Tylenol maker Kenvue said on Monday Thibaut Mongon had stepped down as chief executive officer and board member.

2 months ago - Reuters

Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its ful...

2 months ago - Business Wire